What does CUSIP 92532F100 represent in this 13F holders report?

CUSIP 92532F100 is the security identifier for VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock used to aggregate holder disclosures.

How many institutions held VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock in Q1 2018?

674 institutional investors reported VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock for Q1 2018. Use the holders table for investor-level position and value details.

VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX)

CUSIP: 92532F100

Q1 2018 13F Holders as of 31 Mar 2018

Type / Class: Equity / Common Stock
Shares outstanding: 254,153,218
Total 13F shares: 240,511,936
Share change: +867,176
Total reported value: $39,191,663,333
Put/Call ratio: 95%
Price per share: $162.98
Number of holders: 674
Value change: +$165,476,417
Number of buys: 331
Number of sells: 291

Quarterly Holders Quick Answers

What is CUSIP 92532F100?
CUSIP 92532F100 identifies VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q2 2018
Previous quarter: Q4 2017

Recent filing periods for CUSIP 92532F100:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	11%	28,338,859	$4,246,861,000	—	31 Dec 2017	13F
BlackRock Finance, Inc.	13F	Company	7.6%	19,409,073	$2,908,644,000	—	31 Dec 2017	13F
VANGUARD GROUP INC	13F	Company	7.1%	17,934,504	$2,687,665,000	—	31 Dec 2017	13F
FMR LLC	13F	Company	6.6%	16,731,833	$2,507,432,000	—	31 Dec 2017	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	4.9%	12,384,194	$1,855,897,000	—	31 Dec 2017	13F
STATE STREET CORP	13F	Company	4.3%	10,976,063	$1,644,877,000	—	31 Dec 2017	13F
JPMORGAN CHASE & CO	13F	Company	3.7%	9,397,952	$1,408,376,000	—	31 Dec 2017	13F
Clearbridge Investments, LLC	13F	Company	2.6%	6,685,669	$1,001,914,000	—	31 Dec 2017	13F
Capital World Investors	13F	Company	2.3%	5,889,483	$882,598,000	—	31 Dec 2017	13F
JENNISON ASSOCIATES LLC	13F	Company	2.2%	5,537,907	$829,911,000	—	31 Dec 2017	13F
AMERIPRISE FINANCIAL INC	13F	Company	2.1%	5,255,380	$786,892,000	—	31 Dec 2017	13F
GOLDMAN SACHS GROUP INC	13F	Company	1.3%	3,230,201	$484,078,000	—	31 Dec 2017	13F
Invesco Ltd.	13F	Company	1.2%	3,109,494	$465,987,000	—	31 Dec 2017	13F
WADDELL & REED FINANCIAL INC	13F	Company	1.1%	2,858,847	$428,427,000	—	31 Dec 2017	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	1.1%	2,847,917	$426,789,000	—	31 Dec 2017	13F
NORTHERN TRUST CORP	13F	Company	1.1%	2,843,320	$426,100,000	—	31 Dec 2017	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1%	2,607,251	$389,878,000	—	31 Dec 2017	13F
NORGES BANK	13F	Company	0.92%	2,340,504	$350,748,000	—	31 Dec 2017	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.84%	2,127,092	$318,765,000	—	31 Dec 2017	13F
Bank of New York Mellon Corp	13F	Company	0.79%	2,019,566	$302,653,000	—	31 Dec 2017	13F
FRED ALGER MANAGEMENT, LLC	13F	Company	0.79%	2,018,898	$302,552,000	—	31 Dec 2017	13F
TIAA CREF INVESTMENT MANAGEMENT LLC	13F	Company	0.74%	1,891,482	$283,457,000	—	31 Dec 2017	13F
ORBIMED ADVISORS LLC	13F	Company	0.69%	1,741,300	$260,951,000	—	31 Dec 2017	13F
CITADEL ADVISORS LLC	13F	Company	0.67%	1,714,260	$256,898,000	—	31 Dec 2017	13F
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.6%	1,517,835	$227,463,000	—	31 Dec 2017	13F
BB BIOTECH AG	13F	Company	0.58%	1,475,445	$221,110,000	—	31 Dec 2017	13F
PUTNAM INVESTMENTS LLC	13F	Company	0.57%	1,452,163	$217,621,000	—	31 Dec 2017	13F
Jupiter Investment Management Ltd	13F	Company	0.56%	1,428,127	$214,019,000	—	31 Dec 2017	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.55%	1,402,926	$210,243,000	—	31 Dec 2017	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	0.53%	1,359,281	$203,702,000	—	31 Dec 2017	13F
MORGAN STANLEY	13F	Company	0.51%	1,296,071	$194,229,000	—	31 Dec 2017	13F
AMUNDI ASSET MANAGEMENT US, INC.	13F	Company	0.51%	1,288,046	$193,027,000	—	31 Dec 2017	13F
FRANKLIN RESOURCES INC	13F	Company	0.49%	1,250,992	$187,474,000	—	31 Dec 2017	13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	13F	Company	0.49%	1,241,733	$186,086,107	—	31 Dec 2017	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.48%	1,228,083	$184,041,000	—	31 Dec 2017	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.48%	1,227,412	$183,940,000	—	31 Dec 2017	13F
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	13F	Company	0.47%	1,203,221	$180,315,000	—	31 Dec 2017	13F
PICTET ASSET MANAGEMENT LTD	13F	Company	0.47%	1,197,351	$179,435,000	—	31 Dec 2017	13F
JANUS HENDERSON GROUP PLC	13F	Company	0.46%	1,171,371	$175,542,000	—	31 Dec 2017	13F
Legal & General Group Plc	13F	Company	0.45%	1,151,082	$172,501,000	—	31 Dec 2017	13F
1832 Asset Management L.P.	13F	Company	0.39%	981,100	$144,597,000	—	31 Dec 2017	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.37%	951,176	$142,544,000	—	31 Dec 2017	13F
DEUTSCHE BANK AG\	13F	Company	0.37%	932,477	$139,735,000	—	31 Dec 2017	13F
Swiss National Bank	13F	Company	0.37%	929,009	$139,221,000	—	31 Dec 2017	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.36%	912,724	$136,781,000	—	31 Dec 2017	13F
Manning & Napier Group, LLC	13F	Company	0.36%	902,502	$135,247,000	—	31 Dec 2017	13F
NEW YORK STATE COMMON RETIREMENT FUND	13F	Company	0.33%	840,331	$125,932,000	—	31 Dec 2017	13F
Marshall Wace North America L.P.	13F	Company	0.32%	822,888	$123,318,000	—	31 Dec 2017	13F
PANAGORA ASSET MANAGEMENT INC	13F	Company	0.32%	820,631	$122,980,000	—	31 Dec 2017	13F
TEACHERS ADVISORS, LLC	13F	Company	0.32%	807,725	$121,046,000	—	31 Dec 2017	13F

Institutional Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) as of Q1 2018

As of 31 Mar 2018, VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) was held by 674 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 240,511,936 shares. The largest 10 holders included PRICE T ROWE ASSOCIATES INC /MD/, BlackRock Inc., VANGUARD GROUP INC, FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, STATE STREET CORP, Capital World Investors, JPMORGAN CHASE & CO, JENNISON ASSOCIATES LLC, and Clearbridge Investments, LLC. This page lists 675 institutional shareholders reporting positions in this security for the Q1 2018 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2018 vs Q4 2017 Across Filers

Q4 2017 holders

637

Q1 2018 holders

674

Holder diff

Investor	Q4 2017 Shares	Q1 2018 Shares	Share Diff	Share Chg %	Q4 2017 Value $	Q1 2018 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.